Modulation des Mikrobioms

Der Einfluss der uns kolonisierenden Mikroorganismen, der sog. Mikrobiota, auf unseren Körper ist mittlerweile unumstritten. Diverse Krankheitsbilder stehen in Verbindung mit der Zusammensetzung unseres Mikrobioms. Dessen Veränderungen können Ursache einer Erkrankung, Therapiefolge oder unabhängig davon auftreten. Daher ist die gezielte Modulation der Mikrobiota ein vielversprechender Ansatz in der Prävention sowie Therapie vieler Krankheiten.

Kernaussagen

• Das Mikrobiom weist eine hohe inter- und intraindividuelle Variabilität auf, die durch genetische und Lebensstilfaktoren sowie Umwelteinflüsse gekennzeichnet ist.

• Die Modulation des Mikrobioms lässt sich therapeutisch nutzen.

• Der FMT zeigt eine hohe Wirksamkeit in der Therapie der rezidivierenden CDI. Das Ansprechen erscheint vielversprechend in der Therapie weiterer Erkrankungen.

• Studien zur Pharmakokinetik und Dosisfindung werden benötigt, um die Wirkung von Probiotika zu belegen.

• Die Wirkung von präbiotischen Präparaten muss erst noch ausreichend belegt werden, bevor man den Einsatz im klinischen Alltag empfehlen kann.

• Durch die Modulation von Mikrobiota lässt sich möglicherweise das Therapieansprechen von Patienten beeinflussen.

Publication History

Article published online:
11 March 2020

• Literatur

• 1 Ohland CL, Jobin C. Microbial activities and intestinal homeostasis: A delicate balance between health and disease. Cell Mol Gastroenterol Hepatol 2015; 1: 28-40 DOI: 10.1016/j.jcmgh.2014.11.004.
• 2 Kennedy AD, Wittmann BM, Evans AM. et al. Metabolomics in the clinic: A review of the shared and unique features of untargeted metabolomics for clinical research and clinical testing. Journal of mass spectrometry: JMS 2018; 53: 1143-1154 DOI: 10.1002/jms.4292.
• 3 Smirnov KS, Maier TV, Walker A. et al. Challenges of metabolomics in human gut microbiota research. International journal of medical microbiology: IJMM 2016; 306: 266-279 DOI: 10.1016/j.ijmm.2016.03.006.
• 4 Marchesi JR, Adams DH, Fava F. et al. The gut microbiota and host health: a new clinical frontier. Gut 2016; 65: 330-339 DOI: 10.1136/gutjnl-2015-309990.
• 5 Kashyap PC, Chia N, Nelson H. et al. Microbiome at the Frontier of Personalized Medicine. Mayo Clinic Proceedings 2017; 92: 1855-1864 DOI: 10.1016/j.mayocp.2017.10.004.
• 6 Dang AT, Marsland BJ. Microbes, metabolites, and the gut–lung axis. Mucosal Immunology 2019; 12: 843-850 DOI: 10.1038/s41385-019-0160-6.
• 7 Quigley EMM. Microbiota-Brain-Gut Axis and Neurodegenerative Diseases. Current neurology and neuroscience reports 2017; 17: 94 DOI: 10.1007/s11910-017-0802-6.
• 8 Wiest R, Albillos A, Trauner M. et al. Targeting the gut-liver axis in liver disease. Journal of hepatology 2017; 67: 1084-1103 DOI: 10.1016/j.jhep.2017.05.007.
• 9 Holster S, Lindqvist CM, Repsilber D. et al. The Effect of Allogenic Versus Autologous Fecal Microbiota Transfer on Symptoms, Visceral Perception and Fecal and Mucosal Microbiota in Irritable Bowel Syndrome: A Randomized Controlled Study. Clinical and translational gastroenterology 2019; 10: e00034 DOI: 10.14309/ctg.0000000000000034.
• 10 Hagel S, Fischer A, Ehlermann P. et al. Fecal Microbiota Transplant in Patients With Recurrent Clostridium Difficile Infection. Deutsches Ärzteblatt international 2016; 113: 583-589 DOI: 10.3238/arztebl.2016.0583.
• 11 Khan MY, Dirweesh A, Khurshid T. et al. Comparing fecal microbiota transplantation to standard-of-care treatment for recurrent Clostridium difficile infection: a systematic review and meta-analysis. European journal of gastroenterology & hepatology 2018; 30: 1309-1317 DOI: 10.1097/meg.0000000000001243.
• 12 Dubberke ER, Mullane KM, Gerding DN. et al. Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-Based Drug Targeted at Recurrent Clostridium difficile Infection. Open forum infectious diseases 2016; 3: ofw133 DOI: 10.1093/ofid/ofw133.
• 13 Cammarota G, Ianiro G, Kelly CR. et al. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut 2019; 68: 2111-2121 DOI: 10.1136/gutjnl-2019-319548.
• 14 Upadhyaya B, McCormack L, Fardin-Kia AR. et al. Impact of dietary resistant starch type 4 on human gut microbiota and immunometabolic functions. Scientific reports 2016; 6: 28797-28797 DOI: 10.1038/srep28797.
• 15 Petrof EO, Khoruts A. From Stool Transplants to Next-Generation Microbiota Therapeutics. Gastroenterology 2014; 146: 1573-1582 DOI: https://doi.org/10.1053/j.gastro.2014.01.004.
• 16 Carlucci C, Jones CS, Oliphant K. et al. Effects of defined gut microbial ecosystem components on virulence determinants of Clostridioides difficile. Scientific reports 2019; 9: 885 DOI: 10.1038/s41598-018-37547-x.
• 17 Chase D, Goulder A, Zenhausern F. et al. The vaginal and gastrointestinal microbiomes in gynecologic cancers: a review of applications in etiology, symptoms and treatment. Gynecologic oncology 2015; 138: 190-200 DOI: 10.1016/j.ygyno.2015.04.036.
• 18 DeLong K, Bensouda S, Zulfiqar F. et al. Conceptual Design of a Universal Donor Screening Approach for Vaginal Microbiota Transplant. Frontiers in cellular and infection microbiology 2019; 9: 306 DOI: 10.3389/fcimb.2019.00306.
• 19 Garcia-Velasco JA, Menabrito M, Catalan IB. What fertility specialists should know about the vaginal microbiome: a review. Reproductive biomedicine online 2017; 35: 103-112 DOI: 10.1016/j.rbmo.2017.04.005.
• 20 Stapleton AE. The Vaginal Microbiota and Urinary Tract Infection. Microbiol Spectr 2016; 4 DOI: 10.1128/microbiolspec.UTI-0025-2016.
• 21 Dominguez-Bello MG, De Jesus-Laboy KM, Shen N. et al. Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer. Nature medicine 2016; 22: 250-253 DOI: 10.1038/nm.4039.
• 22 Kundu P, Blacher E, Elinav E. et al. Our Gut Microbiome: The Evolving Inner Self. Cell 2017; 171: 1481-1493 DOI: 10.1016/j.cell.2017.11.024.
• 23 Komesu YM, Dinwiddie DL, Richter HE. et al. Defining the Relationship Between Vaginal and Urinary Microbiomes. American journal of obstetrics and gynecology 2019; DOI: 10.1016/j.ajog.2019.08.011.
• 24 Whiteside SA, Razvi H, Dave S. et al. The microbiome of the urinary tract – a role beyond infection. Nature reviews Urology 2015; 12: 81-90 DOI: 10.1038/nrurol.2014.361.
• 25 Hill C, Guarner F, Reid G. et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature reviews Gastroenterology & hepatology 2014; 11: 506-514 DOI: 10.1038/nrgastro.2014.66.
• 26 Rondanelli M, Faliva MA, Perna S. et al. Using probiotics in clinical practice: Where are we now? A review of existing meta-analyses. Gut Microbes 2017; 8: 521-543 DOI: 10.1080/19490976.2017.1345414.
• 27 Sanders ME, Merenstein DJ, Reid G. et al. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nature Reviews Gastroenterology & Hepatology 2019; DOI: 10.1038/s41575-019-0173-3.
• 28 Maldonado-Gomez MX, Martinez I, Bottacini F. et al. Stable Engraftment of Bifidobacterium longum AH1206 in the Human Gut Depends on Individualized Features of the Resident Microbiome. Cell host & microbe 2016; 20: 515-526 DOI: 10.1016/j.chom.2016.09.001.
• 29 Thomas DW, Greer FR. Probiotics and prebiotics in pediatrics. Pediatrics 2010; 126: 1217-1231 DOI: 10.1542/peds.2010-2548.
• 30 Scaldaferri F, Gerardi V, Mangiola F. et al. Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update. World journal of gastroenterology 2016; 22: 5505-5511 DOI: 10.3748/wjg.v22.i24.5505.
• 31 Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). Fäkale Mikrobiota-Transplantation (FMT, Stuhltransplantation): Risiko für die Übertragung von multiresistenten Erregern. Im Internet: (Stand: 14.02.2020) www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RI/2019/RI-FMT.html
• 32 Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL). Nahrungsergänzungsmittel vs. Arzneimittel. Im Internet: (Stand: 14.02.2020) www.bvl.bund.de/DE/01_Lebensmittel/03_Verbraucher/04_NEM/01_NEM_Arzneimittel/NEM_Arzneimittel_node.html
• 33 Doron S, Snydman DR. Risk and safety of probiotics. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015; 60 (Suppl. 02) S129-134 DOI: 10.1093/cid/civ085.
• 34 Suez J, Zmora N, Zilberman-Schapira G. et al. Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT. Cell 2018; 174: 1406-1423.e1416 DOI: 10.1016/j.cell.2018.08.047.
• 35 Platsidaki E, Dessinioti C. Recent advances in understanding Propionibacterium acnes (Cutibacterium acnes) in acne. F1000Research 2018; 7 DOI: 10.12688/f1000research.15659.1.
• 36 Egert M, Simmering R, Riedel CU. The Association of the Skin Microbiota With Health, Immunity, and Disease. Clinical pharmacology and therapeutics 2017; 102: 62-69 DOI: 10.1002/cpt.698.
• 37 Myles IA, Earland NJ, Anderson ED. et al. First-in-human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitis. JCI Insight 2018; 3: e120608 DOI: 10.1172/jci.insight.120608.
• 38 Knackstedt R, Knackstedt T, Gatherwright J. The role of topical probiotics on skin conditions: A systematic review of animal and human studies and implications for future therapies. Experimental dermatology 2019; DOI: 10.1111/exd.14032.
• 39 Elison E, Vigsnaes LK, Rindom Krogsgaard L. et al. Oral supplementation of healthy adults with 2'-O-fucosyllactose and lacto-N-neotetraose is well tolerated and shifts the intestinal microbiota. Br J Nutr 2016; 116: 1356-1368 DOI: 10.1017/S0007114516003354.
• 40 Maier TV, Lucio M, Lee LH. et al. Impact of Dietary Resistant Starch on the Human Gut Microbiome, Metaproteome, and Metabolome. MBio 2017; 8 DOI: 10.1128/mBio.01343-17.
• 41 Baxter NT, Schmidt AW, Venkataraman A. et al. Dynamics of Human Gut Microbiota and Short-Chain Fatty Acids in Response to Dietary Interventions with Three Fermentable Fibers. MBio 2019; 10: e02566-02518 DOI: 10.1128/mBio.02566-18.
• 42 Costantini L, Molinari R, Farinon B. et al. Impact of Omega-3 Fatty Acids on the Gut Microbiota. Int J Mol Sci 2017; 18: 2645 DOI: 10.3390/ijms18122645.
• 43 Winston JA, Theriot CM. Impact of microbial derived secondary bile acids on colonization resistance against Clostridium difficile in the gastrointestinal tract. Anaerobe 2016; 41: 44-50 DOI: 10.1016/j.anaerobe.2016.05.003.